Table 7 Multivariate regression analysis for predicting eligibility of patients for BCS after neoadjuvant chemotherapy
From: Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
B | Std. error | Wald | Sig. | Exp(B) | 95% confidence interval for Exp(B) | |||
|---|---|---|---|---|---|---|---|---|
Lower bound | Upper bound | |||||||
BCS | Age | − 0.119 | 0.036 | 10.751 | 0.001* | 0.887 | 0.826 | 0.953 |
Menopause (no) | − 1.256 | 0.591 | 4.511 | 0.034* | 0.285 | 0.089 | 0.908 | |
Grade (1vs4) | 0.932 | 0.520 | 3.215 | 0.073 | 2.539 | 0.917 | 7.029 | |
Type (1vs6) | − 0.455 | 0.507 | .803 | 0.370 | 0.635 | 0.235 | 1.715 | |
Stage (1vs7) | − 0.362 | 0.264 | 1.874 | 0.171 | 0.696 | 0.415 | 1.169 | |
ER (no) | − 3.315 | 1.224 | 7.339 | 0.007* | 0.036 | 0.003 | 0.400 | |
PR (no) | 1.390 | 0.772 | 3.241 | 0.072 | 4.016 | 0.884 | 18.248 | |
HER2 (no) | 0.365 | 0.748 | .237 | 0.626 | 1.440 | 0.332 | 6.243 | |
KI67 | 0.469 | 0.456 | 1.056 | 0.304 | 1.598 | 0.654 | 3.910 | |
Chemotherapy | − 1.676 | 0.656 | 6.538 | 0.011 | 0.187 | 0.052 | 0.676 | |